Literature DB >> 23035222

Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Felicia Roscoe1, Ren-Huan Xu, Luis J Sigal.   

Abstract

The orthopoxvirus (OPV) vaccinia virus (VACV) requires an intact F13L gene to produce enveloped virions (EV) and to form plaques in cell monolayers. Simultaneous introduction of an exogenous gene and F13L into F13L-deficient VACV results in expression of the foreign gene and restoration of plaque size. This is used as a method to rapidly generate VACV recombinants without the need for drug selection. However, whether other OPVs require the orthologs of F13L to generate EV and form plaques, whether F13L orthologs and EV are important for OPV pathogenesis in natural hosts, and whether a system based on F13L ortholog deficiency can be used to generate recombinant OPVs other than VACV have not been reported. The F13L ortholog in ectromelia virus (ECTV), the agent of mousepox, is EVM036. We show that ECTV lacking EVM036 formed small plaques and was highly attenuated in vivo but still induced strong antibody responses. Reintroduction of EVM036 in tandem with the DsRed gene resulted in a virus that expressed DsRed in infected cells but was indistinguishable from wild-type ECTV in terms of plaque size and in vivo virulence. Thus, our data show that, like F13L in VACV, EVM036 is required for ECTV plaque formation and that EVM036 and EV are important for ECTV virulence. Our experiments also suggest that OPVs deficient in F13L orthologs could serve as safer anti-OPV vaccines. Further, our results demonstrate that ECTV deficient in EVM036 can be exploited for the rapid generation of fully virulent ECTV expressing foreign genes of interest.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23035222      PMCID: PMC3503138          DOI: 10.1128/JVI.01732-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Construction and isolation of recombinant vaccinia virus using genetic markers.

Authors:  María M Lorenzo; Inmaculada Galindo; Rafael Blasco
Journal:  Methods Mol Biol       Date:  2004

Review 2.  Poxvirus vector-based HIV vaccines.

Authors:  Giuseppe Pantaleo; Mariano Esteban; Bertram Jacobs; Jim Tartaglia
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host.

Authors:  Min Fang; Luis J Sigal
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

4.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Set of vectors for the expression of histidine-tagged proteins in vaccinia virus recombinants.

Authors:  I Galindo; M M Lorenzo; R Blasco
Journal:  Biotechniques       Date:  2001-03       Impact factor: 1.993

6.  Isolation of recombinant MVA using F13L selection.

Authors:  Juana M Sánchez-Puig; María M Lorenzo; Rafael Blasco
Journal:  Methods Mol Biol       Date:  2012

7.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

8.  Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Authors:  Nanhai Chen; Clifford J Bellone; Jill Schriewer; Gelita Owens; Torgny Fredrickson; Scott Parker; R Mark L Buller
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.513

9.  Development of ST-246® for Treatment of Poxvirus Infections.

Authors:  Robert Jordan; Janet M Leeds; Shanthakumar Tyavanagimatt; Dennis E Hruby
Journal:  Viruses       Date:  2010-11-03       Impact factor: 5.818

10.  Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.

Authors:  Douglas W Grosenbach; Aklile Berhanu; David S King; Stacie Mosier; Kevin F Jones; Robert A Jordan; Tove' C Bolken; Dennis E Hruby
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 12.779

View more
  9 in total

1.  Migratory Dendritic Cells, Group 1 Innate Lymphoid Cells, and Inflammatory Monocytes Collaborate to Recruit NK Cells to the Virus-Infected Lymph Node.

Authors:  Eric Wong; Ren-Huan Xu; Daniel Rubio; Avital Lev; Colby Stotesbury; Min Fang; Luis J Sigal
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

2.  The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.

Authors:  Xueying Ma; Ren-Huan Xu; Felicia Roscoe; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Luis J Sigal
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

3.  Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Carolina R Melo-Silva; Colby Stotesbury; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

4.  Langerhans Cells Orchestrate the Protective Antiviral Innate Immune Response in the Lymph Node.

Authors:  Eric Wong; Brian Montoya; Colby Stotesbury; Maria Ferez; Ren-Huan Xu; Luis J Sigal
Journal:  Cell Rep       Date:  2019-12-03       Impact factor: 9.423

5.  Resistance to ectromelia virus infection requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy.

Authors:  Eric B Wong; Brian Montoya; Maria Ferez; Colby Stotesbury; Luis J Sigal
Journal:  PLoS Pathog       Date:  2019-12-26       Impact factor: 6.823

6.  Viral infection modulates Qa-1b in infected and bystander cells to properly direct NK cell killing.

Authors:  Maria Ferez; Cory J Knudson; Avital Lev; Eric B Wong; Pedro Alves-Peixoto; Lingjuan Tang; Colby Stotesbury; Luis J Sigal
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

7.  Defective early innate immune response to ectromelia virus in the draining lymph nodes of aged mice due to impaired dendritic cell accumulation.

Authors:  Colby Stotesbury; Eric B Wong; Lingjuan Tang; Brian Montoya; Cory J Knudson; Carolina R Melo-Silva; Luis J Sigal
Journal:  Aging Cell       Date:  2020-07-12       Impact factor: 9.304

8.  Ectromelia-encoded virulence factor C15 specifically inhibits antigen presentation to CD4+ T cells post peptide loading.

Authors:  Katherine S Forsyth; Nathan H Roy; Elise Peauroi; Brian C DeHaven; Erik D Wold; Adam R Hersperger; Janis K Burkhardt; Laurence C Eisenlohr
Journal:  PLoS Pathog       Date:  2020-08-03       Impact factor: 6.823

Review 9.  An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.

Authors:  Andrew T Russo; Douglas W Grosenbach; Jarasvech Chinsangaram; Kady M Honeychurch; Paul G Long; Candace Lovejoy; Biswajit Maiti; Ingrid Meara; Dennis E Hruby
Journal:  Expert Rev Anti Infect Ther       Date:  2020-09-15       Impact factor: 5.854

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.